Summary of retrospective studies, comparing between different weight groups in patients on DOACs
| Study/Year . | N . | Anticoagulant . | Anticoagulation indications . | Wright group . | Efficacy outcome: thrombotic events . | Safety outcome: major or overt bleeding, % . | |
|---|---|---|---|---|---|---|---|
| Arachchillage et al/201638 | 167 | R | VTE* | >120 kg (n = 44) | 2.3% | 0 | |
| ≤120 kg (n = 123) | 3.3% | 1.6 | |||||
| Aloi et al/201939 | 1196 | D, R, A | VTE | ≥120 kg (n = 133) | 0.8% | OR, 0.66; 95% CI, 0.09-5.14; P = .69 | N/A |
| <120 kg (n = 1063) | 1.1% | ||||||
| Netley et al/201940 | 3458 | D, R, A | VTE and AF | BMI > 40 kg/m2 (n = 595) | 1.5% | 1.2 | |
| BMI ≤ 40 kg/m2 (n = 2863) | 1.2% | 2.2 | |||||
| Study/Year . | N . | Anticoagulant . | Anticoagulation indications . | Wright group . | Efficacy outcome: thrombotic events . | Safety outcome: major or overt bleeding, % . | |
|---|---|---|---|---|---|---|---|
| Arachchillage et al/201638 | 167 | R | VTE* | >120 kg (n = 44) | 2.3% | 0 | |
| ≤120 kg (n = 123) | 3.3% | 1.6 | |||||
| Aloi et al/201939 | 1196 | D, R, A | VTE | ≥120 kg (n = 133) | 0.8% | OR, 0.66; 95% CI, 0.09-5.14; P = .69 | N/A |
| <120 kg (n = 1063) | 1.1% | ||||||
| Netley et al/201940 | 3458 | D, R, A | VTE and AF | BMI > 40 kg/m2 (n = 595) | 1.5% | 1.2 | |
| BMI ≤ 40 kg/m2 (n = 2863) | 1.2% | 2.2 | |||||
A, apixaban; D, dabigatran; OR, odds ratio; R, rivaroxaban. See Table 1 for expansion of other abbreviations.
Median follow-up, 14 months.